Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances
Expectations High For Precision Medicine, Artificial Intelligence And RNA Technologies
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
You may also be interested in...
In this week's podcast version of Five Must-Know Things: Amgen launches first US biosimilar to Humira; strong launches set to help BMS as it faces losses of exclusivity; Eisai preaches patience on Leqembi for Alzheimer’s; 10 clinical trials to watch for this year; and Scrip Asks what 2023 holds in store for biopharma technological advances.
From a scientific perspective, the outlook for patient with rare disease has never been brighter. This year, 13 new cell or gene therapies could be approved in the US, Europe or both by the end of 2023. However, the challenges that stop patients accessing new therapies remain. Could this year be the turning point when our health care systems start to catch up with our science?
The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.